The meal-driven, graduated progression of insulin therapy in this way, rather than immediately embarking on a full basal–bolus regimen or introducing premixed insulin preparations, may be more relevant and acceptable to a large number of persons with Type 2 diabetes and their physicians alike. This evidence concerns the gene INS and type 2 diabetes mellitus.